{
  "source": "PA-Notification-Attruby.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1466-1\nProgram Prior Authorization/Notification\nMedication Attruby™ (acoramidis)\nP&T Approval Date 1/2025\nEffective Date 4/1/2025\n1. Background:\nAttruby (acoramidis) is a transthyretin stabilizer indicated for the treatment of the\ncardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults\nto reduce cardiovascular death and cardiovascular-related hospitalization.\n2. Coverage Criteriaa:\nA. Transthyretin (ATTR)-mediated amyloidosis with cardiomyopathy (ATTR-CM)\n1. Initial Authorization\na. Attruby will be approved based on all of the following criteria:\n(1) Diagnosis of transthyretin (ATTR)-mediated amyloidosis with cardiomyopathy\n(ATTR-CM)\n-AND-\n(2) Patient is not receiving Attruby in combination with an RNA-targeted therapy for\nATTR amyloidosis [i.e., Amvuttra (vutrisiran), Onpattro (patisiran), Tegsedi\n(inotersen), Vyndaqel/Vyndamax (tafamadis), or Wainua (eplontersen)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Attruby will be approved based on both of the following criteria:\n(1) Documentation that the patient has experienced a positive clinical response to\nAttruby (e.g., improved symptoms, quality of life, slowing of disease progression,\ndecreased hospitalizations, etc.)\n-AND-\n(2) Patient is not receiving Attruby in combination with an RNA-targeted therapy for\nATTR amyloidosis [i.e., Amvuttra (vutrisiran), Onpattro (patisiran), Tegsedi\n(inotersen), Vyndaqel/Vyndamax (tafamadis), or Wainua (eplontersen)]\nAuthorization will be issued for 12 months.\n© 2025 UnitedHealthcare Services, Inc.\n1\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Programs:\n• Medical Necessity may be in place\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and ",
    "icies and utilization management\nprograms may apply.\n3. Additional Clinical Programs:\n• Medical Necessity may be in place\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-\n10) and/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Attruby [package insert]. BridgeBio Pharma, Inc: Palo Alto, CA; November 2024.\nProgram Prior Authorization/Notification - Attruby™ (acoramidis)\nChange Control\n1/2025 New program.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}